Digital & Innovation
Pfizer partners to advance machine learning for drug discovery

Digital & Innovation: A biotechnology company specialising in machine learning (ML) solutions for preclinical drug discovery, announced a strategic partnership with Pfizer with the goal of accelerating small molecule drug discovery by developing a platform technology based on generative chemistry.
PostEra’s ML technology is intended to accelerate the drug discovery process by designing novel molecular structures with optimised potency and drug-like properties.
Through the collaboration, the companies will leverage Pfizer’s extensive data and expertise with PostEra’s technology capabilities to advance the science of generative chemistry to produce state-of-the-art, scalable models that could potentially be deployed across in-house, preclinical drug discovery efforts.
PostEra will receive an upfront payment and is eligible to receive additional payments as the project progresses. PostEra will also retain ownership rights to all algorithms developed during the collaboration.
“We believe that our investments in machine learning technologies could potentially help us expedite preclinical drug discovery. PostEra’s technology complements this effort, and we look forward to seeing the results of the collaboration,” said Charlotte Allerton, Head of Medicine Design, Pfizer.
“PostEra is delighted to be working with Pfizer to solve some of the key pain points in preclinical drug discovery,” said Aaron Morris, CEO of PostEra. “As a team we are proud to be entering this collaboration and will be leveraging PostEra’s many advances in machine learning to help Pfizer accelerate progress toward novel therapeutics.”
News & Trends - MedTech & Diagnostics

Medtech, academia and government unite: Breaking down silos to deliver the power and promise of digital health to patients
MedTech & Diagnostics News: In an interview with Health Industry Hub, Annette Schmiede, CEO of Digital Health Cooperative Research Centre […]
MoreNews & Trends - MedTech & Diagnostics

Two-decade evolution of robotic surgery in Australia’s medical landscape
MedTech & Diagnostics News: In the past two decades, what was once deemed impossible in surgery has now become a […]
MoreNews & Trends - Pharmaceuticals

World-first in IVF: Merging AI and genomics to optimise treatment response for Australians
Pharma News: A world-first Australian IVF study exploring genome sequencing has garnered enthusiastic reception from its collaborative research partners. Securing […]
MoreNews & Trends - Pharmaceuticals

PBS listing marks first oral therapy for childhood arthritis
Pharma News: The first oral Janus kinase (JAK) inhibitor, Pfizer’s Xeljanz (tofacitinib), has been listed on the Pharmaceutical Benefits Scheme […]
More